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A B S T R A C T
The aim of the current work was to develop generic sustained-release tablets containing
35 mg trimetazidine dihydrochloride and to establish an in vitro–in vivo correlation that could
predict the bioavailability. The marketed sustained release tablet (Vastarel MR) used as ref-
erence, a sustained-release matrix tablet was prepared using hydroxypropyl methylcellulose
(HPMC) as matrix by wet granulation and the in vitro dissolution profiles of the self-made
tablets were determined in four different dissolution media (0.1 M HCl, pH 4.5 PBS, pH 6.8
PBS and water). A higher similarity between prepared tablets and Vastarel MR was estab-
lished, with similarity factor (f2) ranging from 60 to 75 in the four media. The in vivo
pharmacokinetics was studied in six healthy beagles. Compared with Vastarel MR, the Cmax
of self-made tablets was slightly decreased, while the Tmax and MRT0–t were slightly pro-
longed, but with no significant difference (P > 0.05). The average of relative bioavailability
(F) was 102.52% based on AUC0–t. For log-transformed AUC0–t and Cmax, the upper confidence
limit on the appropriate criterion is <0, indicating these two formulations were population
bioequivalent. The in vivo–in vitro correlation coefficient obtained from point-to-point analy-
sis of self-made tablets was 0.9720. In conclusion, the prepared tablets were bioequivalent
to the marketed tablets, according to both the in vitro release rate and extent of absorp-
tion, and a good in vivo–in vitro correlation was established for the self-made tablets that
indicated in vitro dissolution tests could be used as a surrogate for bioavailability studies.
© 2016 Production and hosting by Elsevier B.V. on behalf of Shenyang Pharmaceutical
University. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
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The marketed sustained release tablet (Vastarel MR) used as reference, a generic sustained-release tablet of trimetazidine hydro-
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1. Introduction
Angina pectoris, commonly known as angina, is a clinical mani-
festation of ischemic heart disease, generally arising from
obstruction or spasm of the coronary arteries [1,2]. In pa-
tients with angina pectoris, myocardial ischemia induces lower
exercise capacity, more frequent angina attacks and reduces
quality of life [3]. Trimetazidine dihydrochloride, 1-[(2,3,4-
trimethoxyphenyl) methyl] piperazin is a clinically effective
antianginal agent that has been used in the prophylaxis and
management of angina pectoris [4]. Unlike other classical
antianginal drugs, such as beta-blockers, calcium-channel
antagonists, and long-acting nitrates, trimetazidine di-
hydrochloride displays anti-ischemic effects without induc-
ing hemodynamic changes and thus protects the heart from
the deleterious consequences of ischemia. So it is generally well
tolerated and accompanied by minor side effects. Besides,
trimetazidine dihydrochloride is freely soluble in water and has
a relatively short half-life of 6 ± 1.4 h. Therefore, it is consid-
ered as an ideal candidate for sustained drug delivery [5].
In the market, trimetazidine dihydrochloride is available as
both immediate release oral formulations (Vastarel IR, 20 mg)
and modified release tablets (Vastarel MR, 35 mg). The optimal
dosage regimen of IR tablets is approved three times a day while
MR tablets is twice a day [6]. However, repeated administra-
tion of the IR tablets leads to poor compliance for angina
pectoris patients who need a long term therapy. MR tablets with
sustained drug release behaviors could maintain their thera-
peutically effective concentrations in systemic circulation for
prolonged periods of time, which decreases the number of daily
administrations, minimizing local and systemic side effects.
Thus it improves the patient compliance with prescribed dosage
regimens [7].
Hydrophilic polymers are becoming very popular in for-
mulating oral sustained release tablets, such as xanthan gum,
cellulose derivatives, alginate sodium or carbopol [8].
Hydroxypropyl methylcellulose (HPMC) is the most com-
monly and successfully used hydrophilic material for sustained
drug delivery [9]. It possesses some important characteristics
including nontoxicity, pH independence and high water
swellability, which contribute to obtain a desirable drug sus-
tained release profile. In this investigation, HPMC was used as
a release retardant carrier in the design of sustained release
matrix tablets for trimetazidine dihydrochloride.
Besides, a point-to-point in vitro–in vivo correlation was de-
veloped for relating percentage of drug dissolved to percentage
of drug absorbed. The Food and Drug Administration (FDA)
defines in vitro–in vivo correlation as a predictive mathemati-
cal model describing the relationship between an in vitro
property of a dosage form and a relevant in vivo response [10].
A good correlation could predict the rate and extent of drug
absorption in vivo [11]. Developing an in vitro–in vivo correla-
tion for a sustained release tablet is an important object to
facilitate product development and serves as a quality control
procedure during product manufacture. This reduces the need
for expensive bioavailability testing in animals and humans
[12].
Hence the objective of the work was to prepare oral ad-
ministration of sustained release HPMC matrix tablets
containing 35 mg trimetazidine dihydrochloride and study its
bioequivalence to marketed formulations (Vastarel MR). Similar
studies of the dissolution in vitro of these two formulations (self-
made and marketed sustained release tablets) have been
performed in four different dissolution media (0.1 M HCl, pH 4.5
PBS, pH 6.8 PBS and water). Their bioavailability and pharma-
cokinetic studies were conducted in beagles. Besides, the in vitro–
in vivo correlation of self-made tablets was developed and used
as a tool for predicting in vivo bioavailability based on in vitro
dissolution data.
2. Materials and methods
2.1. Materials
Trimetazidine dihydrochloride was kindly supplied by Wuhan
Wu Pharmaceutical Company, China. Hydroxypropyl methyl-
cellulose (HPMC) and ethyl cellulose were purchased from
Shanghai Colorcon Pharmaceutical Co. (Shanghai, China). Stearic
acid was provided by Hunan Er-kang Pharmaceutical Co., Ltd.
(China). Polyvinylpyrrolidone K30 (PVP K30) was purchased from
Sinopharm Chemical Reagent Co., Ltd. (China). Docosanoic acid
glycerol ester was purchased from Guangzhou Tianrui Phar-
maceutical Co., Ltd. (China). Calcium hydrogen phosphate
dehydrate and potassium dihydrogen phosphate were pur-
chased from Huzhou Zhanwang Pharmaceutical Co., Ltd.
(China). Microcrystalline cellulose, starch and magnesium stea-
rate were provided by Shandong Ahua Pharmaceutical Co., Ltd.
(China). Sodium heptane-1-sulfonate was purchased from
Tianjin Kermel Company. Trichloroacetic acid and Potassium
dihydrogen phosphate was purchased from Tianjin Damao
Chemical Reagent Co., Ltd. Ethanol was provided by Tianjin fu
yu Chemical Reagent Co.,Ltd. Acetonitrile (HPLC grade) and
methanol (HPLC grade) were high-performance liquid chro-
matography (HPLC) grade. Double distilled water was used
throughout the study.
Animal: Beagles (female or male were provided by Drug
Safety Assessment Center of Shandong Institute of Materia
Medica) were used for the in vivo pharmacokinetic studies.
2.2. Preparation and optimization of trimetazidine
dihydrochloride sustained release tablets
The sustained release tablets of trimetazidine dihydrochloride
were prepared using wet granulation method. After being
grinded and sifted, required quantities of drug, HPMC and ex-
cipients were mixed thoroughly, subsequently passed through
an 80-mesh screen (stainless steel) to blend the ingredients uni-
formly. The powder blend was moistened with the required
amount of wetting agent (2% HPMC E50LV in 80% ethanol so-
lution or 8% PVP K30 in 80% ethanol solution or 80% ethanol)
and then pressed through a 30-mesh screen to prepare wet
granules. The granules were dried at 45–55 °C for 2 h and the
moisture content was controlled within 3% to 5%. The dried
granules were then retained on 30-mesh screen (stainless steel),
mixed with a prescribed amount of magnesium stearate as lu-
bricant. Finally, the tablets were compressed using a flat-
faced 8-mm punch in single-punch press tablet machine. Each
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tablet contained 35 mg of trimetazidine dihydrochloride, keeping
hardness between 5.0 and 7.0 kgf.
To study the influences of the tablet formulation,
trimetazidine dihydrochloride sustained release matrix tablets
were prepared according to the orthogonal design (Table 1).The
three major factors were set as follows: A, the amount of HPMC;
B, the amount of blocking agents; C, the amount of loading
agents. The similarity factor (f2) was employed to evaluate the
release profiles of various formulations compared with the
release profile of marketed tablets. In the orthogonal experi-
mental design, f2 was chosen as the evaluation index.
2.3. Tablet weight variation
Weight variation tests of marketed tablets and three batches
of self-made tablets were done respectively.Twenty tablets were
weighed to obtain the average tablet weight and the individual
tablet weight was compared to the average. And then weight
variation was evaluated for utilizing criteria based on the
Chinese Pharmacopoeia (ChP).
2.4. In vitro dissolution studies
The release studies of trimetazidine dihydrochloride from the
self-made and marketed sustained release tablets were per-
formed according to the ChP paddle method. Studies were
carried out at (37 ± 0.5) °C and 50 rpm rotation speed in 900 mL
of 0.1 M HCl, pH 4.5 PBS, pH 6.8 PBS and water, respectively.The
amount of drug used was equivalent to 35 mg. Five milliliters
of the dissolution samples were withdrawn at different time
intervals (0.5, 1, 2, 4 and 8 h) and were replaced with equal
volume of fresh release medium to maintain a constant total
volume [13]. Samples were filtered through 0.45 μm millipore
filter and assayed for drug content by a UV spectrophotom-
eter at λmax of 231 nm after appropriate dilution. Moreover,
the selectivity of the UV method was studied by comparing
UV spectrum of blank excipients with those of correspond-
ing trimetazidine dihydrochloride standard solution. As a result,
no interference from excipients was observed at λmax of
231 nm (Fig. 1).
Cumulative amount of trimetazidine dihydrochloride dis-
solved in the preparations was calculated using calibration
curves. Dissolution tests were carried out in six vessels per
Table 1 – Factors and levels of orthogonal experiment for
trimetazidine dihydrochloride sustained release tablets
Levels A (mg/tablet) B (mg/tablet) C (mg/tablet)
1 52.5 5 50
2 70 10 75
3 87.5 15 100
Fig. 1 – UV spectrums for trimetazidine dihydrochloride (a) and blank excipients (b) in 0.1 M HCl (Fig. 1A), pH 4.5 PBS
(Fig. 1B), pH 6.8 PBS (Fig. 1C) and water (Fig. 1D).
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formulation (n = 6). The similarity factor (f2) was used as a basis
to compare the difference between self-made tablets and mar-
keted tablets in dissolution profiles, which was calculated using
the following equation [14].
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where n is the number of time points for tested samples, Rt
is the dissolution value of the reference batch at time t, and
Tt is the dissolution value of the test batch at time t. The simi-
larity factor ( f2 ) is a measurement of the similarity in the
percent dissolution between the two curves. And f2 values
greater than 50 (50–100) ensure sameness or equivalence of the
two curves.
2.5. Drug release mechanism
The description of in vitro dissolution profiles was analyzed
using the following mathematical models with different equa-
tions [15].
Zero order model M M k tt: ∞ = 0
First order model M M k tt: ln 1 1− = −( )∞
Higuchi model M M k tt H: ∞ = 1 2
Ritger-Peppas model M M k tt k n: ∞ =
where Mt is the amount of drug released at time t, M∞ the total
amount of drug, k0 is zero order release rate constant, k1 is first
order release rate constant and kH is the Higuchi rate con-
stant. Besides, n is the release exponent (e.g. first order release
when n = 1), describing the kinetic and the drug release oper-
ating mechanism for cylindrical shaped matrices.
In the Ritger–Peppas model, the value of n, representing the
diffusion pattern, n ≤ 0.45, corresponds to a Fickian diffusion
mechanism, 0.45 < n < 0.89 to anomalous non-Fickian trans-
port, n = 0.89 to Case II transport, and n > 0.89 to super case II
transport [16]. The correlation coefficient (r) was used as an in-
dicator of the best fitting, for each of the models considered.
2.6. In vivo pharmacokinetics study in beagles
2.6.1. Study design
The study was conducted to compare the pharmacokinetics
of trimetazidine from the self-made tablets to commercially
available tablets (Vastarel MR, 35 mg), following the adminis-
tration of single doses equivalent to 70 mg (two tablets per dose),
each using a non-blind, two-treatment, two-period, random-
ized, crossover design. Six healthy beagle dogs of either sex
were selected for experiment and divided into two groups (3
animals in each) randomly.The dogs were fasted for about 12 h
before the study, while water was provided freely as much they
required.
The study was performed on two phases. In Phase I, half
the number of beagle dogs received the self-made tablet and
the remainder received the commercially available tablet which
is considered as a standard. Both treatments were ingested with
250 ml of water, while no food was allowed for 4 h after dosing.
A washout period of 1 week separated the phases. In Phase
II, the reverse of randomization took place. Venous blood
samples (3 ml) were withdrawn and taken into heparinized
tubes at 0, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 24 and 30 h after
administration of each treatment. The blood samples were im-
mediately centrifuged at 3000 rpm for 10 min, plasma obtained
by and stored at −20 °C until analysis by HPLC.
2.6.2. Chromatographic conditions
The quantitative determination of trimetazidine dihydrochloride
in plasma was performed using a modified HPLC method of Min
Kyo Jeoung et al. [17]. Chromatographic separation was per-
formed at 30 °C on reversed-phase C18 column (4.6 μm × 150 mm).
The mobile phase consisted of potassium dihydrogen phos-
phate (0.05 mol/l, pH was adjusted to 4.0 with 10% phosphoric
acid) and methanol (76:24, v/v) and was delivered to the system
at the flow rate of 1.0 ml/min with UV detection at 210 nm.
2.6.3. Standard solutions
A 500 μl aliquot of blank plasma was accurately measured into
a 5-mL centrifuge tube, spiked with appropriate standard so-
lutions to produce concentrations of 25, 50, 100, 200, 500, 1000,
2000 ng/ml of trimetazidine dihydrochloride. 100 μl of 10% (w/
v) trichloroacetic acid was added to the above plasma samples,
which was vortexed for 3 min and centrifuged for 12 min at
12,000 rpm [18]. The resulting supernatant liquid contained
20.83, 41.67, 83.33, 166.67, 416.67, 833.33, 1666.67 ng/ml
trimetazidine dihydrochloride in plasma, respectively. And then
20 μl of each sample was injected into the column for analy-
sis. Under the described conditions, the retention time of
trimetazidine dihydrochloride was about 12.8 min. A stan-
dard curve was established by plotting the peak area of
trimetazidine dihydrochloride against its concentration in
plasma. The lower limit of quantification was 20.83 ng/ml. The
method showed good linearity (R2 = 0.9987) in the range of 20.83–
1666.67 ng/ml in beagles plasma.The mean extraction recoveries
of trimetazidine dihydrochloride were 85–115%, RSD < 7%. The
inter-day and intra-day relative standard deviations (RSDs) for
trimetazidine were less than 12% at the above concentrations.
2.6.4. Pharmacokinetic analysis
Pharmacokinetic analysis of the two treatments was per-
formed for each dog by using DAS2.0 (drug and statistics for
windows) program. Maximum drug concentration (Cmax) and
the corresponding time to Cmax (Tmax) were obtained from the
plasma concentration-time curves directly. The area under the
curves, AUC0–t (ng h/ml), was calculated by the trapezoidal rule
from 0 to 30 h. On the other hand, AUC0–∞ (ng h/ml), the area
under the curve from zero to infinity, was calculated as
AUC0–∞ = AUC0–t + Ct/Ke, where, Ct is the drug plasma concen-
tration observed at time t and Ke is the apparent elimination
rate constant. Half-life (t1/2) was obtained by dividing 0.693 with
Ke. Mean residence time (MRT) was calculated from AUMC/
AUC. The relative bioavailability (F) of the self-made tablet was
calculated by dividing its AUC0–t with that of marketed sus-
tained release dosage form [19].
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2.6.5. Statistical analysis
The results were expressed as mean ± standard deviation (SD).
The comparison between two groups was performed using un-
paired Student’s t-test, a significant level of difference for the
tests was considered at a level of P < 0.05. The pharmacoki-
netic parameters of the two groups were analyzed using the
DAS 2.0 software package (Chinese Pharmacological Society).
2.7. In vitro–in vivo correlation
A point-to-point in vitro–in vivo correlation of self-made tablets
was developed for relating percentage of drug in vitro disso-
lution to percentage of drug in vivo absorbed. Based on a good
correlation, measuring the in vitro dissolution rate alone is suf-
ficient to determine the pharmacokinetic profile in vivo. It allows
the in vivo bioavailability test with the fewest possible trials
in animals and man for the prepared formulation.
The fraction of the drug absorbed ( Fa) was calculated by the
Wagner–Nelson Eq. (1) or by the Loo–Riegelman Eq. (2) for both
a one-compartment model and the two-compartment model
[20].
F
C k AUC
k AUC
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t t
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10 0
10 0
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where Fa is the fraction of the drug absorbed, Ct is the con-
centration of drug in the plasma at time point t, k10 is the
elimination rate constant, AUC t0− is the calculated area under
the plasma concentration curve from zero to time t, and AUC0−∞
is the calculated area under the plasma concentration curve
from time zero to infinity. X Vt C is the apparent tissue com-
partment concentration at the time t. The percent of drug
absorbed ( Fa) at the specified time points was plotted against
the percent of drug dissolved in vitro at the same time points.
The linear regression coefficient (R2) was used to evaluate the
correlation between in vitro release and in vivo absorption.
3. Results and discussions
3.1. Optimization of formulation of trimetazidine
dihydrochloride sustained release matrix tablets
3.1.1. Results of the test of orthogonal design
Based on preliminary study, three factors were chosen as re-
search objects, including A, B and C. Furthermore, the factors
affecting f2 were studied in orthogonal experimental design.
Table 2 showed the results of drug release and orthogonal
design. The range (R) among the score averages is the differ-
ence between the highest and the lowest score average.
According to Table 2, the effect of B (the amount of blocking
agents) was extremely significant; the effect of other factors
was not significant. The effects of each factor on the f2 were
as follows: B (the amount of blocking agents) > A (the amount
of HPMC) > C (the amount of loading agents). K1a, K2a and K3a
were the average sum scores of Level 1, Level 2 and Level 3 for
each factor, respectively. Apparently, the larger the average sum
score was the closer to the release profile of marketed tablets.
Analytical results of three factors were A: 3 > 2 > 1, B: 3 > 2 > 1,
C: 3 > 2 > 1, so the optimal formulation was found to be A3B3C3
and it was obtained as follows: HPMC, 87.5 mg; blocking agents,
15 mg; loading agents, 100 mg.
3.1.2. Lot reproducibility
Three batches of the trimetazidine dihydrochloride sus-
tained release tablet were prepared by the optimal formulation
and the in vitro release tests were performed. Batches I, II and
III showed similarity factor f2 values of 71.41, 69.16 and 67.60,
respectively. Hence, the drug release from the three batches
tablets was similar to that of the marketed product (Vastarel
MR, 35 mg). Moreover, ANOVA test shows that batches I, II and
III are not significantly different in their drug release profile
(P > 0.05 at each time point) and the values of f2 (P > 0.05). The
batch reproducibility study indicated that the formulation meth-
odology employed was found to be suitable for trimetazidine
dihydrochloride sustained release tablets.
Table 2 – Results of orthogonal experiment design.
Run Factors Release rate (%) Similarity factor
A B C 0.5 h 1 h 2 h 4 h 8 h f2
1 1 1 1 32.02 45.47 63.61 86.34 97.71 50.55
2 1 2 2 27.46 39.82 56.32 77.77 92.88 69.17
3 1 3 3 26.91 38.11 54.17 75.98 91.95 75.02
4 2 1 2 30.58 44.00 61.39 83.53 96.74 60.94
5 2 2 3 24.13 35.45 50.96 71.17 92.52 83.12
6 2 3 1 24.50 35.87 51.37 71.18 90.05 75.50
7 3 1 3 24.33 33.11 47.34 66.92 86.82 62.44
8 3 2 1 25.26 34.86 49.21 69.90 91.65 76.32
9 3 3 2 26.62 38.09 55.59 76.21 95.27 86.82
K1a 64.91 57.98 67.46
K2a 73.19 76.20 72.31
K3a 75.19 79.11 73.53
R 10.28 21.13 6.07
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3.2. Tablet weight variation
The results of weight variation are shown in Table 3. Average
weights of marketed tablets and three batches of self-made
tablets were calculated as 0.2105, 0.2033, 0.2043, 0.2067, re-
spectively (n = 20). As shown in Table 3, no tablet deviated from
the average weight by more than 7.5% and indicated that the
self-made tablets were obtained of uniform weight.
3.3. In vitro dissolution studies
In the present study, the in vitro dissolution studies were carried
out for the self-made sustained release tablets in four differ-
ent dissolution media (0.1 M HCl, pH 4.5 PBS, pH6.8 PBS and
water) and the release profiles are shown in Fig. 2. It is clear
that the self-made sustained release tablets released about 20%
of its trimetazidine dihydrochloride content in the four media
after 0.5 h and the amount of the drug released in 8 h was not
less than 80% of the labeled amount in the four media. More-
over, the in vitro release behavior of the self-made formulation
was not affected by pH of dissolution medium. These results
suggested that the self-made tablet exhibited a slow release
in vitro which is independent of the pH of dissolution media.
Besides, the results of the in vitro release of trimetazidine
dihydrochloride from the self-made sustained release tablets
in comparison with that of market product (Vastarel MR) in
four media are graphically shown in Table 4 and Fig. 3. As shown
in Table 4, the similarity factor f2 was used to compare the two
dissolution profiles, and the results showed the f2 values ranged
from 60 to 75, indicating that the self-made sustained release
tablets shared a similar drug in vitro release behaviors with the
marketed tablets. Dissolution studies revealed it is expected
to provide a new excellent candidate for trimetazidine
dihydrochloride sustained release tablets in the market.
3.4. Drug release mechanism studies
The in vitro release studies were carried out for the marketed
and self-made sustained release tablets in 0.1 M HCl, water,
and phosphate buffers with pH 4.5 and 6.8 media. In order to
determine the suitable drug release kinetic model, the in vitro
release data were analyzed according to zero-order model, first-
order model, Higuchi model and Ritger–Peppas model.
Correlation is higher as absolute value of the correlation co-
efficient (r) is closer to 1.
Firstly, analysis was performed by the zero order model, first
order model and Higuchi model equations. In case of the mar-
keted tablets, the correlation coefficient (r) values for Higuchi
model were found to be higher in 0.1M HCl (0.9988) and water
Table 3 – Results of tablet weight variation.
No Marketed (g) Batch 1 (g) Batch 2 (g) Batch 3 (g)
1 0.2112 0.2039 0.2023 0.2084
2 0.2149 0.1978 0.2052 0.2073
3 0.2101 0.2067 0.2045 0.2042
4 0.2211 0.2038 0.2065 0.2079
5 0.2128 0.2015 0.2035 0.2060
6 0.2059 0.2016 0.2037 0.2120
7 0.2075 0.2046 0.2026 0.2095
8 0.2107 0.2090 0.2076 0.2045
9 0.2100 0.1998 0.2059 0.2070
10 0.2110 0.2040 0.2040 0.2107
11 0.2100 0.2059 0.2059 0.2040
12 0.2061 0.2020 0.2040 0.2020
13 0.2081 0.2030 0.2043 0.2051
14 0.2073 0.2003 0.2055 0.2044
15 0.2102 0.2005 0.2066 0.2052
16 0.2107 0.2026 0.1987 0.2065
17 0.2112 0.2061 0.2082 0.2100
18 0.2103 0.2023 0.2011 0.2019
19 0.2106 0.2045 0.2032 0.2059
20 0.2110 0.2074 0.2018 0.2093
Average weight (g) 0.2105 0.2033 0.2043 0.2067
The limit of weight variation % ±7.5% ±7.5% ±7.5% ±7.5%
Upper and lower limits of weight (g) 0.1947–0.223 0.1880–0.215 0.1890–0.216 0.1912–0.222
Result Qualified Qualified Qualified Qualified
Fig. 2 – Dissolution profiles of trimetazidine
dihydrochloride from self-made sustained release tablets
in 0.1 M HCl, pH 4.5 PBS, pH 6.8 PBS and water.
422 a s i an j o u rna l o f p h a rma c eu t i c a l s c i e n c e s 1 1 ( 2 0 1 6 ) 4 1 7 – 4 2 6
media (0.9974), when compared to that of first order kinetics
and zero order kinetics. However, the ‘r’ values for the first order
release kinetics were found to be higher in phosphate buffers
with pH 4.5 (0.9991) and 6.8 media (0.9987), when compared
to that of zero order kinetics and Higuchi model. It indicates
that the release of trimetazidine dihydrochloride from mar-
keted sustained release tablets was fitted to Higuchi model in
0.1 M HCl and water media, while the drug release followed
first order kinetics in phosphate buffers with pH 4.5 and 6.8
media (Table 5). From Table 5, for the self-made formulation,
first-order kinetics had the higher regression value com-
pared to the zero and Higuchi kinetics in four media, which
indicates that the release of trimetazidine dihydrochloride from
the prepared sustained release tablets was fitted well with the
first-order in the four media. In addition, the dissolution data
of self-made and marketed tablets were fitted to the Ritger–
Peppas model; the diffusion exponent values ranged between
0.45 and 0.89, but were close to 0.45, which appears to indi-
cate trimetazidine hydrochloride was released from the two
sustained-release formulations by the synergistic effect of dif-
fusion and erosion skeleton, but with diffusion serving as the
main release way. This may be attributed to the high water-
solubility of the trimetazidine dihydrochloride in the sustained
release matrix tablets.
3.5. In vivo pharmacokinetics study in beagle dogs
Pharmacokinetic studies of self-made sustained release tablets
(test tablets) of trimetazidine dihydrochloride compared with
commercially available sustained-release tablets (reference
tablets) were investigated. The plasma drug concentrations of
the two sustained-release tablets at different time intervals were
determined respectively. And the mean concentration-time pro-
files for test and reference tablets are shown in Fig. 4. Similar
to the commercially available products, a steady plasma con-
centration of trimetazidine dihydrochloride was obtained for
the self-made sustained release tablets. Most importantly, the
Table 4 – The cumulative amount of drug release (Ft) from the self-made and marketed tablets and the calculated
similarity factor (f2) for trimetazidine dihydrochloride dissolution profiles obtained from self-made tablets compared to
the marketed tablets.
Medium Sample Ft (%) f2
0.5 h 1 h 2 h 4 h 8 h 12 h
0.1 M HCl Marketed 25.83 35.51 49.62 72.47 97.12 100.66 69.36
Self-made 23.55 33.86 49.64 67.98 89.98 97.29
pH 4.5PBS Marketed 24.53 35.94 51.31 71.28 88.87 94.27 74.88
Self-made 22.13 33.07 47.06 67.61 88.99 97.23
pH 6.8PBS Marketed 27.12 37.63 53.97 74.46 90.51 94.50 56.59
Self-made 21.47 31.00 45.60 64.85 85.10 93.55
Water Marketed 24.55 35.76 51.80 73.03 96.36 102.14 61.32
Self-made 21.49 31.91 47.25 67.18 86.76 92.95
Fig. 3 – Comparison of in vitro dissolution profiles of self-made sustained release tablet and the marketed tablet in 0.1 M
HCl (a), pH 4.5 PBS (b), pH 6.8 PBS (c) and water (d), respectively.
423a s i an j o u rna l o f p h a rma c eu t i c a l s c i e n c e s 1 1 ( 2 0 1 6 ) 4 1 7 – 4 2 6
plasma concentration of trimetazidine dihydrochloride did not
differ significantly after administration of both formulations.
The parameters Tmax and AUC0–∞ are related to the rate and
extent of absorption, respectively, while Cmax is related to both
processes [21]. The values of the pharmacokinetic parameters
of the prepared and marketed tablets are given in Table 6. The
mean Cmax values for self-made sustained release tablets and
marketed product were 628.17 ng/ml and 688.00 ng/ml, respec-
tively, reached after time (Tmax) 2.6 h and 2.2 h, respectively.
Besides, the values of mean residence time (MRT0–t) of
trimetazidine dihydrochloride in self-made and marketed tablets
were 7.682 h and 6.608 h, respectively. Compared with the mar-
keted sustained release tablets, the Cmax of self-made tablets was
slightly decreased, while the Tmax and MRT0–t were slightly pro-
longed. However, statistical analysis revealed that there was no
significant difference (P > 0.05) in the values of Cmax, Tmax and
MRT0–t obtained from self-made and marketed tablets.The rela-
tive bioavailability (F) of test tables compared to reference tables
was calculated to be 102.52% based on AUC0–t (Table 6).
DAS 2.0 software was used to perform the population
bioequivalent (PBE) statistical analyses. For log transformed ob-
servations AUC0–t and Cmax, the upper confidence limit on the
appropriate was <0, indicating these two formulations were
population bioequivalent. Moreover, test for the analyzed Tmax
showed no significant differences (P = 0.26 > 0.05).Then it could
be established that the self-made tablets were bioequivalent
to the marketed sustained release tablets and that both for-
mulations could be considered equally effective and safe in
therapeutics in angina pectoris patients.
Thus, the drug release behavior from self-made sustained
release tablets in vivo was similar to the commercially avail-
able products, evidenced by the similarity in their pharma-
cokinetic parameters; moreover, the two formulations were
population bioequivalent based on AUC0–t and Cmax. There-
fore, the self-made tablets were bioequivalent to commercially
available sustained-release tablets, and the two formulations
are interchangeable.
3.6. In vivo–in vitro correlation
The IVIVC for trimetazidine dihydrochloride was examined.The
optimization one compartment models was determined for the
drug dosage forms after validation by DAS2.0 (drug and sta-
tistics for windows) program. Therefore, in vivo–in vitro
correlation was investigated using the percentage of drug
release in a water medium of self-made sustained release
tablets and the drug absorption fraction in beagle dogs at fasted
condition.The accumulative absorption fraction of trimetazidine
dihydrochloride was calculated according to the Loo–Riegelman
method. As shown in Fig. 5, the correlation coefficient (R2)
between the drug release from the tablets and absorption of
drug was 0.9720, indicating that the drug release correlated well
with the fraction absorption. Therefore, the in vivo absorption
behavior could be predicted by the test of in vitro drug release.
4. Conclusions
The present study was carried out for the prepared sustained
release tablets of trimetazidine dihydrochloride compared with
Table 5 – Mathematic model fitting of release profile of
self-made and marketed trimetazidine dihydrochloride
sustained release tablets.
Medium Model Marketed
tablets
Self-made
tablets
r n r n
0.1 M HCl Zero-order model 0.9792 0.9701
First-order model 0.9858 0.9990
Higuchi model 0.9988 0.9971
Ritger–Peppas
model
0.9994 0.4851 0.9981 0.4874
pH 4.5PBS Zero-order model 0.9562 0.9709
First-order model 0.9991 0.9997
Higuchi model 0.9919 0.9972
Ritger–Peppas
model
0.9955 0.4702 0.9980 0.5047
pH 6.8PBS Zero-order model 0.9508 0.9698
First-order model 0.9987 0.9997
Higuchi model 0.9891 0.9969
Ritger–Peppas
model
0.9952 0.4562 0.9981 0.5039
Water Zero-order model 0.9709 0.9645
First-order model 0.9912 0.9996
Higuchi model 0.9974 0.9951
Ritger–Peppas
model
0.9983 0.4975 0.9967 0.5101
Fig. 4 – Plasma concentration profiles of trimetazidine
dihydrochloride of self-made and marketed release tablets
after oral administration to six healthy beagles under
fasted conditions (mean ± SD).
Table 6 – Pharmacokinetic parameters of trimetazidine
dihydrochloride in beagles (n = 6) administered with
marketed tablets (dose 35 mg) and prepared tablets
(dose 35 mg).
Parameter Marketed tablets Prepared tablets
Cmax (ng/ml) 688.00 ± 256.89 628.17 ± 223.24
Tmax (h) 2.2 ± 0.7 2.6 ± 0.7
MRT0–t (h) 6.608 ± 2.003 7.682 ± 2.132
MRT0–∞ (h) 24.221 ± 39.970 15.350 ± 10.308
AUC0–t (ng h/ml) 4552.031 ± 863.267 4581.547 ± 1258.561
AUC0–∞ (ng h/ml) 6157.509 ± 3596.719 5606.011 ± 1727.253
F (AUC0–t) – 102.52 ± 28.06
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the commercially available modified release tablets (Vastarel
MR, 35 mg). For the dissolution studies in vitro, the f2 factor con-
firmed that the release of trimetazidine dihydrochloride from
the prepared tablets was similar to that of the marketed tablets.
Results from in vivo pharmacokinetics study in beagle dogs
also clearly indicated that the variability in the prepared
trimetazidine dihydrochloride absorption profiles was equiva-
lent to the marketed products. The in vivo comparative study
results confirmed that the pharmacokinetic parameters AUC
and the Cmax of trimetazidine dihydrochloride were similar after
oral administration with the self-made and the marketed sus-
tained released tablets. Besides, compared with the marketed
tablets, the relative bioavailability judged from the AUC0–t was
found to be 102.52%. Moreover, the two formulations were popu-
lation bioequivalent based on AUC0–t and Cmax. Thus, it could
be concluded the self-made sustained release tablets were
bioequivalent to the branded products in the market (Vastarel
MR, 35 mg), which proved that the prepared tablets can be used
interchangeably with Vastarel MR. The in vitro–in vivo correla-
tion coefficient (R2) was 0.9720, suggesting that the prepared
tablets followed a strong correlation between in vitro release
and pharmacokinetic effect; moreover, it seemed to be rea-
sonable to predict the drug absorption in vivo through the in
vitro release study. Therefore, the high correlation between in
vitro dissolution and in vivo absorption could be used to fore-
cast the in vivo bioavailability with allowing dosage form
optimization with the fewest possible trials in animals and man.
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